Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

A Lilly USA LLC employee fired for allegedly misusing a corporate credit card failed to mount a viable claim that he was ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

BRISBANE, Australia & INDIANAPOLIS, IN, USA I 10, 2025 I AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha ...

Eli Lilly and Co Patrik Jonsson; Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA; Eli Lilly and Co Anne White; Executive Vice President, President - Lilly ...